All news

Progyny expands into menopause research, Barclays stays Hold

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Progyny will present new menopause research on October 22, 2026, extending its healthcare offerings beyond fertility into a full reproductive health continuum. Barclays maintained a Hold rating on the stock with a USD 30.00 price target. The company also cites an outlook of 1.2 million new covered lives, pairing broader commercial reach with clinical evidence for employers.

Read original source

PGNY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.